A Phase 2, Placebo-Controlled, Randomized, Double-Blinded, Multicenter, Study To Evaluate The Bleeding Profile Of 2.5 Mg And 5.0 Mg Bid Apixaban In Combination With Standard Therapy In Patients With Recent (less than or equal to 7 Days) Acute Coronary Syndrome (ACS).
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2013
At a glance
- Drugs Apixaban (Primary)
- Indications Acute coronary syndromes; Thrombosis
- Focus Adverse reactions
- Acronyms APPRAISE-J
- 22 Aug 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jul 2010 Planned end date changed from 1 Oct 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History